Image Kyrapharm

A strategic
and industrial agreement

History

On September 13th 2013, the Japanese Fuji Silysia Group and the French group Axyntis signed a strategic industrial agreement. A joint venture, Kyrapharm, was created as a result of this agreement. The two groups invested €3 million. This investment enabled the acquisition of the assets of Kiralya and the establishment of the company on Orgapharm industrial site (a subsidiary of the Axyntis Group) in Pithiviers (Loiret).
Kyrapharm is developing chromatography activity with a dedicated team of ten or so people.

In 2004, Kiralya company (8 people) acquired most of its assets from Sanofi Aventis. Main activity was purification by chromatography of chemical products primarily intended for the field of pharmaceutical research and development. It targeted pharmaceutical, cosmetic, veterinary and neutraceutical markets and involved pharmaceutical molecules under development or in phase I or II.

The Japanese group Fuji Silysia, created in 1931, is one of the global leaders in silica technology. Fuji Silysia produces and distributes a wide range of silica gels, micronized silica and products derived from silica (desiccants, dehumidifying compounds, absorbents, phases for chromatography) which cater to the needs of its clients or provide them with added value in markets as diverse as plastics, coatings, food, cosmetics and pharmaceutical products. Fuji Silysia has four plants in Japan as well as two research centres. The group also has 6 sales offices in Japan and around the world as well as two subsidiaries, one in the United States and another in Europe.
www.fuji-silysia.co.jp/english/

The Axyntis Group, an intermediate-sized company with estimated turnover of €100 M in 2014 and more than 420 employees, is a leading speciality chemicals company in France thanks to its GMP capabilities (700 m3). The group owns six sites (All’Chem in Montluçon, Centipharm in Grasse, Orgapharm in Pithiviers, Steiner in Saint Marcel and Synthexim in Calais, withtwo sites) and three R&D centres, all located in France. Its activities revolve around the life sciences (pharmacy, animal health, agrochemicals), dyes and speciality fine chemicals (electronics, photography, cosmetics, flavourings and perfumes, etc.)
www.axyntis.com

Orgapharm, located in Pithiviers, is a subsidiary of the Axyntis Group. The site employs 95 people and has a total reactor volume of 90 m3. It has been inspected by the Food and Drug Administration (last inspection in 2014), the French National Agency for Drug and Health Product Safety (ANSM) and is also ISO 14001 certified. Main Axyntis Research & Development centre is located at Orgapharm, together with a GMP pilot plant as well as multipurpose synthesis plants and an automated GMP crystallisation/finishing unit. The entire production cycle is covered, from the laboratory to industrial production, thereby enabling support for a project in its entirety.